MIAMI & BARRANQUILLA, Colombia / Nov 14, 2023 / Business Wire / Procaps Group (NASDAQ: PROC) (“Procaps”), a leading integrated LatAm healthcare and pharmaceutical services company, today announced that it is postponing the previously-announced earnings conference call (currently scheduled for November 16, 2023) to a later date after Procaps publishes its results for the third quarter and nine months ended September 30, 2023 ("3Q23”). Procaps will host a conference call in conjunction with its release of the 3Q23 Results, and call/webcast details will be provided in advance of the call.
About Procaps Group
Procaps Group, S.A. (“Procaps”) (NASDAQ: PROC) is a leading developer of pharmaceutical and nutraceutical solutions, medicines, and hospital supplies that reach more than 50 countries in all five continents. Procaps has a direct presence in 13 countries in the Americas and more than 5,500 employees working under a sustainable model. Procaps develops, manufactures, and markets over-the-counter (OTC) pharmaceutical products and prescription pharmaceutical drugs (Rx), nutritional supplements and high-potency clinical solutions.
For more information, visit Procaps’ investor relations website investor.procapsgroup.com.
Last Trade: | US$2.81 |
Daily Change: | 0.05 1.81 |
Daily Volume: | 3,984 |
Market Cap: | US$317.020M |
December 26, 2023 November 29, 2023 November 22, 2023 October 23, 2023 October 02, 2023 |
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORERecursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB